{"product_id":"generic-erlotinib-lucierlo","title":"LuciErlo (Erlotinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eErlotinib is a kinase inhibitor indicated for:\u003c\/p\u003e\u003cp\u003e· The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.\u003c\/p\u003e\u003cp\u003e· First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.\u003c\/p\u003e\u003cp\u003eLimitations of Use:\u003c\/p\u003e\u003cp\u003e· Safety and efficacy of LuciErlo have not been established in patients with NSCLC whose tumors have other EGFR mutations.\u003c\/p\u003e\u003cp\u003e· LuciErlo is not recommended for use in combination with platinumbased chemotherapy.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e· NSCLC: 150 mg orally, on an empty stomach, once daily.\u003c\/p\u003e\u003cp\u003e· Pancreatic cancer: 100 mg orally, on an empty stomach, once daily.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954031659,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0843.jpg?v=1787022214","url":"https:\/\/xomeds.com\/products\/generic-erlotinib-lucierlo","provider":"XOMEDS","version":"1.0","type":"link"}